{"entity":{"id":"nct04765059","kind":"trial","name":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)","aka":["COMPEL"],"tldr":"A phase 3 trial of Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","summary":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT04765059 by AstraZeneca, with 98 participants enrolled, started 2021-09-12 and due to reach its primary completion in 2024-10-28. Interventions recorded: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin. Conditions listed: Non-small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04765059","url":"https://clinicaltrials.gov/study/NCT04765059"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["osimertinib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04765059-esmo-open-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04765059","phase":"3","setting":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients With EGFRm, Locally Advanced or Metastatic NSCLC Who Have Progressed Extracranially Following First-Line Osimertinib Therapy (COMPEL)","sponsor":"AstraZeneca","started":"2021-09-12","startedType":"actual","yearReported":2026,"enrolled":98,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression Free Survival (PFS)","primary":true,"unit":"months","arms":[{"name":"Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin","n":49,"value":8.4,"note":"95% CI 5.75 to 11.83; Figures from the ClinicalTrials.gov results section (first posted 2026-01-13), not from a publication"},{"name":"Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin","n":49,"value":4.4,"note":"95% CI 3.52 to 5.55"}],"hr":0.43,"ci":[0.27,0.7],"source":"https://clinicaltrials.gov/study/NCT04765059?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin","n":49,"value":15.9,"note":"95% CI 12.39 to 20.83; Figures from the ClinicalTrials.gov results section (first posted 2026-01-13), not from a publication"},{"name":"Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin","n":49,"value":9.8,"note":"95% CI 8.38 to 17.25"}],"hr":0.71,"ci":[0.42,1.23],"source":"https://clinicaltrials.gov/study/NCT04765059?tab=results"}]},"route":"/trials/nct04765059/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"paper":[{"id":"paper-nct04765059-esmo-open-2025","kind":"paper","name":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","route":"/key-papers/paper-nct04765059-esmo-open-2025/"}]}}